From: Clinical relevance and biology of circulating tumor cells
 |  |  |  | n (%) |  |  | |||
---|---|---|---|---|---|---|---|---|---|
Detection method | Patient status | Remarks | Total number of patients | CTC+, DTC+ | CTC+, DTC- | CTC-, DTC+ | CTC-, DTC- | Concordance (%) | Reference |
Pan-CK staining | M0 and M1 | - | 114 | 26 (22.8) | 2 (1.7) | 41 (35.9) | 45 (39.4) | 62.3 | [35] |
Pan-CK staining | M0 and M1 | - | 53 | 3 (5.6) | 2 (3.7) | 6 (11.3) | 42 (79.2) | 84.9 | [21] |
RT-PCR | M0 and M1 | Detection of CK19 | 148 | 8 (5.4) | 14 (9.5) | 34 (22.9) | 92 (62.2) | 67.5 | [33] |
CK19 or mammaglobin | M0 and M1 | Detection of mammaglobin | 148 | 11 (7.4) | 18 (12.2) | 19 (12.8) | 100 (67.6) | 75.0 | [33] |
CK-staining | M0 | - | 341 | 8 (2.3) | 26 (7.6) | 40 (11.7) | 267 (78.3) | 80.6 | [29] |
Pan-CK staining | M0 and M1 | - | 39 | 12 (30.8) | 3 (7.6) | 12 (30.8) | 12 (30.8) | 61.5 | [34] |
RT-PCR, CK19 | M0 | Patients before neo-adjuvant therapy | 165 | 88 (53.3) | 3 (1.8) | 7 (4.2) | 67 (40.6) | 93.9 | [31] |
 |  | Patients after neo-adjuvant therapy | 84 | 32 (38.1) | 12 (14.2) | 11 (13.1) | 29 (34.5) | 72.6 | [31] |
CellSearch®, RT-PCR | M0 | High-risk patients | 27 | 16 (59.2) | 4 (14.8) | 3 (11.2) | 4 (14.8) | 74.1 | [22] |
Pan-CK staining, CellSearch® | M0 | - | 63 | 5 (7.9) | 13 (20.6) | 15 (23.8) | 30 (47.6) | 55.5 | [18] |
Avarage | Â | Â | Â | Â | Â | Â | Â | 72.8 | Â |
Minimum | Â | Â | Â | Â | Â | Â | Â | 55.5 | [18] |
Maximum | Â | Â | Â | Â | Â | Â | Â | 93.9 | [31] |